Drug makers AstraZeneca and Amgen have launched new asthma drug texepelumb-ekko, branded as TEZSPIRE,  following approval from the US Food and Drug Administration in December. The drug is currently available for sale in the US market for the treatment of severe asthma in patients above 12 years of age, the companies said in a joint statement, adding that TEZSPIRE is a first-in-class biologic therapy for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. The companies expressed hopes that the drug would help reduce the complexity of severe asthma and the risk of hospitalizations and subsequently, increase the quality of life for asthma patients.